ASCO 2023 | PRISMA: observing PSMA expression in metastatic TNBC

Guilherme Nader Marta, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of the PRISMA study, which examines the feasibility of radioligand therapy in patients with metastatic triple negative breast cancer (TNBC). A number of patients were found to have uptake of PSMA during imaging, suggesting the use of PSMA-directed radioligand therapy in a subset of patients with TNBC. Additional research in biomarkers will be needed to identify patients who will benefit from this strategy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.